ストックスクリーナーアプリを入手
2.20
1.85%
0.04
アフターアワーズ：
2.20
Cardiol Therapeutics Inc (CRDL) 最新ニュース
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cardiol Therapeutics Inc. (TSX:CRDL) Climbs 10.18% as Phase III Catalyst and CardiolRx Momentum Strengthen Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Falls 5.92% as Clinical Trial Uncertainty and Biotech Sector Volatility Pressure Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? - kalkine.ca
Cardiol Therapeutics Inc Class A (CRDL) Peer Comparison – Compare with Others - Value Research
Cardiol Therapeutics Inc. (TSX:CRDL) Gains Momentum as Clinical Pipeline Progress and Heart Disease Therapies Drive Investor Optimism - kalkine.ca
B.Riley initiates Cardiol Therapeutics stock with buy rating on pericarditis drug potential - Investing.com Canada
Cardiol Therapeutics (TSX:CRDL) Rallies 7% as Analyst Upgrades Build on Trial Progress - kalkine.ca
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Cardiol (CRDL) Earnings Snapshot: EPS Lands Above Forecast in the Latest Reading; Share Move: The Stock Loses 1.33% at the CloseMargin Expansion Trends - vinanet.vn
Cardiol (CRDL) Close: Ends Lower by 1.33% at $1.86 in Latest Trading; Technical View: the Supplied Trading Band Runs From $1.77 to $1.95 in the Current UpdateIPO Entry Watch - vinanet.vn
Cardiol Therapeutics Stock Falls 3.33% as Investors Weigh Phase III MAVERIC Promise Against Clinical-Trial and Biotech Execution Risk - kalkine.ca
Cardiol Therapeutics Drops as Biotech Risk Appetite Fades — Could the Next Clinical Update Change Everything? - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Stock Price, Trades & News - GuruFocus
Cardiol (CRDL) Quarterly Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Price Move: The Stock Ends Down 2.04% in the Current UpdateCFO Commentary Report - vinanet.vn
Cardiol Therapeutics Stock Surges 4.82% as Phase III Progress and CardiolRx Pipeline Support Investor Optimism - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock went up yesterday - Wealth Awesome
Cardiol (CRDL) Financial Results: EPS Exceeds Its Estimate in the Latest Reading; Market Move: The Stock Gains 5.28% on the DayEarnings Manipulation Risk - vinanet.vn
Cardiol Therapeutics Stock: A Pivotal Pericarditis Readout Draws Nearer - kalkine.ca
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
CRDL Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
CRDL Q1 2026 Earnings: Narrower-Than-Expected Loss Underscores Pipeline Cost DisciplineShare Dilution Risk - vinanet.vn
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Cardiol Therapeutics (CRDL) Advances 5.26% as Shares Test Key Resistance Near $1.89IPO Entry Watch - vinanet.vn
Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price - MarketBeat
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Could Cardiol Therapeutics Stock Be Entering a Major Catalyst Phase as MAVERIC Enrollment Nears Completion? - kalkine.ca
Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst - MarketBeat
Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome
Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks
Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
What’s Next For Cardiol Therapeutics (TSX:CRDL) Research? - Kalkine Media
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - MarketBeat
Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome
Cardiol Therapeutics at Canaccord Genuity: Phase III catalyst nears By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSX:CRDL): The Oral Heart Drug Challenging Injectable Biologics Nears Its Big Test - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday - MarketBeat
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics to Present Heart Disease Pipeline at Canaccord Genuity Growth Conference - TipRanks
Cardiol Therapeutics Inc. (NASDAQ: CRDL) at Canaccord 46th Growth Conference - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference - The Globe and Mail
Cardiol Therapeutics (CRDL) Holds Steady at $1.30 as Shares Consolidate Between Support and ResistancePullback Trade - dars.gov.et
Cardiol's Pivotal Phase III Heart Trial Reaches 75% Enrolment as Leading U.S. Medical Centres Join the Race - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
Cardiol Therapeutics Inc. (TSX:CRDL) Shares Decline as Biotech Risk, Clinical Uncertainty and Investor Caution Pressure Outlook - kalkine.ca
Cardiol Therapeutics Stock Climbs 3.66%: Clinical Development Progress and Biotechnology Innovation Strengthen Investor Confidence - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
1.66%
0.33%
大文字化:
|
ボリューム (24 時間):